Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, T-Cell

Explore clinical trials studying Lymphoma, T-Cell. Study availability and eligibility vary by location and protocol.

181 public trials 52 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, T-Cell trial results

Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +33 more
Locations
  • University of California at Los Angeles Los Angeles, California, United States
  • Stanford University School of Medicine Stanford, California, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
  • University of Chicago Hospital Chicago, Illinois, United States
View all 15 locations
View Trial Details
Completed

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT00554827

Conditions
Cutaneous T-Cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +15 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Stanford University School of Medicine Redwood City, California, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Emory University Atlanta, Georgia, United States
View Trial Details
Completed

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

NCT00723099

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +63 more
Locations
  • University of Colorado Hospital Aurora, Colorado, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • LDS Hospital Salt Lake City, Utah, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
View Trial Details
Completed

Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT00364923

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California at Los Angeles Los Angeles, California, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Emory University Atlanta, Georgia, United States
View all 32 locations
View Trial Details
Completed

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

NCT01076543

Conditions
AIDS-Related Hodgkin Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +27 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Decatur Memorial Hospital Decatur, Illinois, United States
  • Ingalls Memorial Hospital Harvey, Illinois, United States
View Trial Details
Completed

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients

NCT01822886

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • A.O. SS. Antonio e Biagio e C. Arrigo Alessandria, Italy
  • Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola Bologna, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy
  • A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino Torino, Italy
View Trial Details
Completed

Risk Stratification of Nodal PTCL

NCT03040206

Conditions
Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T-cell Lymphoma, Hemic and Lymphatic Diseases, +13 more
Locations
  • Chonbuk Nationla University Hospital Jeonju, South Korea
View Trial Details

Related conditions